Patent · US Active

IL-32 monoclonal antibodies and uses thereof

US7641904B2 · kind B2 · utility

4Cited by
11References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 15, 2008
Grant dateJan 5, 2010
Priority date
Expiry dateFeb 15, 2028

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S530/809
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present invention provides monoclonal antibodies specific for interleukin-32 (IL-32, previously referred to as “natural killer cell transcript 4” or “NK4”) and hybridomas secreting monoclonal antibodies specific for IL-32. Also provided are diagnostic methods and kits (e.g., ELISA, Western blot, etc.) which utilize monoclonal antibodies specific for IL-32.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.